

Correction

Correction: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. *Antibiotics* 2024, 13, 874

Cristina Kirkegaard-Biosca ^{1,2}, Ester del Barrio-Tofiño ³, Miguel Villamarín ¹, Nieves Larrosa ^{2,3,4}, David Campany ⁵, Juan José González-López ^{2,3,4}, Ricard Ferrer ^{2,6,7}, Belén Viñado ³, Laura Doménech ⁵, Julia Sellarès-Nadal ^{1,2}, Laura Escolà-Vergé ^{2,4,8}, Nuria Fernández-Hidalgo ^{1,2,4,*} and Ibai Los-Arcos ^{1,2,4,*}

¹ Infectious Diseases Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain; cristina.kirkegaard@vallhebron.cat (C.K.-B.); miguel.villamarin@vallhebron.cat (M.V.)

² Department of Medicine, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain; nieves.larrosa@vallhebron.cat (N.L.); juanjo.gonzalez@vallhebron.cat (J.J.G.-L.); ricard.ferrer@vallhebron.cat (R.F.); lescola@santpau.cat (L.E.-V.)

³ Microbiology Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain; ester.delbarrio@vallhebron.cat (E.d.B.-T.); belen.vinado@vallhebron.cat (B.V.)

⁴ CIBERINFEC, ISCIII—CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain

⁵ Pharmacy Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain; david.campany@vallhebron.cat (D.C.); laura.domenech@vallhebron.cat (L.D.)

⁶ Critical Care Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain

⁷ Sepsis Organ Dysfunction and Resuscitation (SODIR) Research Group, Vall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain

⁸ Infectious Diseases Unit, Internal Medicine Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain

* Correspondence: nuria.fernandezhidalgo@vallhebron.cat (N.F.-H.); ibai.losarcos@gmail.com (I.L.-A.)



Received: 28 November 2024

Accepted: 13 December 2024

Published: 24 December 2024

Citation: Kirkegaard-Biosca, C.; del Barrio-Tofiño, E.; Villamarín, M.; Larrosa, N.; Campany, D.; González-López, J.J.; Ferrer, R.; Viñado, B.; Doménech, L.; Sellarès-Nadal, J.; et al. Correction: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. *Antibiotics* 2024, 13, 874.

Antibiotics **2025**, *14*, 4. <https://doi.org/10.3390/antibiotics14010004>

Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Error in Table 2

In the original publication [1], there was a mistake in Table 2, published as follows: Patients 1 and 23 presented clinical failure at day 14, as reported in the text. In addition, by error patient 23 should also appear as mortality at day 30: Yes, and patient 24 mortality at day 30 should be No.

The corrected version of Table 2 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Table 2. Demographic, clinical, and outcome characteristics of the 34 patients with infections caused by VIM-type-producing Gram-negative bacteria treated with cefiderocol.

Patient	Age, yr (Sex)	Underlying Disease	CCI	Type of Infection	Bacterial Species	Bacteremia	Drainable Source/Drainage Performed	Additional Therapy	Days of Treatment	Clinical Failure at Day 14	Mortality at Day 30
1	82 (M)	Renal transplant recipient	7	Primary bacteremia	<i>P. aeruginosa</i>	Yes	No	No	8	Yes	Yes
2	89 (M)	Chronic ischemia right lower limb	14	Chronic osteomyelitis	<i>E. cloacae</i>	No	Yes/Yes: Limb amputation	No	13	No	Yes
3	63 (M)	Lung transplant recipient	2	Previous ECMO cannula wound infection	<i>Raoultella ornithinolytica</i> , <i>E. coli</i>	No	Yes/Yes: Resection of the infected wound	No	13	No	No
4	76 (F)	Diverticulitis	4	Postoperative deep wound infection	<i>Achromobacter</i> sp., <i>P. aeruginosa</i>	No	Yes/No: Undrained abscess	No	8	No	No
5	56 (M)	COVID-19 pneumonia	3	Primary bacteremia and ECMO cannula infection	<i>Achromobacter</i> sp.	Yes	Yes/No: ECMO cannula not retired	Intravenous colistin (after 22 days of cefiderocol)	27	Yes	Yes
6	39 (M)	COVID-19 pneumonia in a lung transplant recipient	1	ECMO cannula wound infection + tracheobronchitis	<i>P. aeruginosa</i>	No	Yes/No: ECMO cannula not retired	Nebulized colistin	6	Yes	Yes
7	51 (M)	Acute pancreatitis	2	Catheter-associated urinary infection	<i>Achromobacter</i> sp.	No	No	No	11	No	Yes
8	78 (F)	Renal transplant recipient	10	Femoro-femoral bypass graft infection	<i>E. cloacae</i>	No	Yes/No: By-pass not explanted	No	13	No	No
9	65 (M)	Renal transplant recipient	6	Obstructive pyelonephritis	<i>E. cloacae</i> , <i>P. aeruginosa</i>	Yes	Yes/Yes: Ureteral stent placement	No	27	No	No
10	59 (M)	Acute myeloid leukemia and recent allo-HSCT	3	Tonsillar abscess	<i>P. aeruginosa</i>	Yes	Yes/No: Undrained abscess	Intravenous amikacin (during the first 3 days)	22	Yes	Yes

Table 2. Cont.

Patient	Age, yr (Sex)	Underlying Disease	CCI	Type of Infection	Bacterial Species	Bacteremia	Drainable Source/Drainage Performed	Additional Therapy	Days of Treatment	Clinical Failure at Day 14	Mortality at Day 30
11	41 (M)	NK/T-cell lymphoma	2	Infected pancreatic necrosis	<i>P. aeruginosa</i>	No	Yes/Yes: Abscess drainage	No	62	No	No
12	56 (F)	Follicular lymphoma with persistent COVID-19	2	Catheter-associated UTI	<i>Achromobacter</i> sp.	No	No	No	5	No	No
13	67 (M)	Lung transplant recipient	2	Acute tracheobronchitis	<i>P. aeruginosa</i>	No	No	Nebulized colistin	7	No	No
14	77 (F)	Acute myeloid leukemia	5	Soft tissue infection	<i>P. aeruginosa</i>	No	No	No	14	No	No
15	61 (M)	Hemorrhagic shock	7	Catheter-associated UTI	<i>Achromobacter</i> sp.	No	No	No	7	No	Yes
16	56 (M)	Tibial osteomyelitis	0	Chronic osteomyelitis	<i>P. putida</i>	No	Yes/Yes: Osteomyelitis debridement	No	14	No	No
17	70 (M)	COPD	5	Nosocomial pneumonia	<i>P. aeruginosa</i>	Yes	No	No	25	No	Yes
18	51 (M)	Renal transplant recipient	3	Renal graft pyelonephritis	<i>P. aeruginosa</i>	No	No	No	17	No	No
19	54 (M)	Elbow osteomyelitis	1	Osteosynthesis-associated infection	<i>E. cloacae</i>	No	Yes/Yes: Osteosynthesis implant removal	No	32	No	No
20	58 (M)	Renal transplant recipient	4	Postoperative deep wound infection	<i>P. aeruginosa</i>	No	Yes/No: Undrained abscess	No	28	No	No
21	67 (M)	Lung transplant recipient	4	Acute tracheobronchitis	<i>P. aeruginosa</i>	Yes	No	Nebulized colistin	15	No	No
22	54 (F)	Lung transplant recipient	3	Acute tracheobronchitis	<i>Enterobacter hormaechei</i>	No	No	Nebulized amikacin	6	No	No
23	45 (M)	Richter's Syndrome	2	Intestinal bacterial translocation	<i>P. aeruginosa</i>	Yes	No	No	9	Yes	Yes
24	53 (F)	Open tibia fracture	1	Tibial osteomyelitis	<i>P. aeruginosa</i>	No	Yes/Yes: Osteomyelitis debridement	No	38	No	No

Table 2. Cont.

Patient	Age, yr (Sex)	Underlying Disease	CCI	Type of Infection	Bacterial Species	Bacteremia	Drainable Source/Drainage Performed	Additional Therapy	Days of Treatment	Clinical Failure at Day 14	Mortality at Day 30
25	54 (F)	Metastatic kidney cancer	5	Catheter-related bloodstream infection	<i>P. aeruginosa</i>	Yes	Yes/Yes: Catheter removal	No	5	No	No
26	78 (F)	Renal transplant recipient	9	Postoperative deep wound infection	<i>P. putida</i>	No	Yes/Yes: Abscess drainage	No	41	No	No
27	44 (F)	Renal transplant recipient	3	Postoperative deep wound infection	<i>P. putida</i>	No	Yes/No: Undrained abscess	No	12	No	No
28	49 (M)	Lung transplant recipient	4	Acute tracheobronchitis	<i>P. aeruginosa</i>	No	No	No	14	No	No
29	75 (M)	Status epilepticus	3	Ventilator-associated pneumonia	<i>P. aeruginosa</i>	No	No	Nebulized colistin	9	No	No
30	77 (M)	Multiple organ dysfunction syndrome	8	Acute tracheobronchitis	<i>P. aeruginosa</i>	No	No	No	10	No	No
31	59 (F)	Pulmonary fibrosis	1	Acute tracheobronchitis	<i>P. aeruginosa</i>	No	No	Nebulized colistin	8	No	No
32	80 (M)	Meige syndrome (tracheostomy)	4	Acute tracheobronchitis	<i>P. aeruginosa</i>	No	No	Nebulized aztreonam	10	No	No
33	56 (M)	Acute lymphoblastic leukemia	4	Prostatic abscess	<i>P. aeruginosa</i>	No	Yes/No: Undrained abscess	No	33	No	No
34	63 (M)	Renal transplant recipient	5	Renal graft pyelonephritis	<i>P. putida</i>	No	No	No	18	No	No

Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation; CCI, Charlson comorbidity index; ECMO, extracorporeal membrane oxygenation; F, female; M, male; UTI, urinary tract infection; and COPD, chronic obstructive pulmonary disease.

Reference

1. Kirkegaard-Biosca, C.; del Barrio-Tofiño, E.; Villamarín, M.; Larrosa, N.; Company, D.; González-López, J.J.; Ferrer, R.; Viñado, B.; Doménech, L.; Sellarès-Nadal, J.; et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. *Antibiotics* **2024**, *13*, 874. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.